Related Videos - | JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Stéphane Oudard¹, Constance Thibault², Antoine Angelergues²

¹Service de cancérologie médicale, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université Paris-Descartes, Sorbonne-Paris-Cité, France; INSERM U970 PARCC université Paris-Descarte, Paris France.

Bulletin Du Cancer

|January 7, 2017

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making.

European urology oncology·2026

Same author

Evaluating the Surrogacy of Pathological Complete Response at Radical Cystectomy in Neoadjuvant-based Muscle-invasive Bladder Cancer Trials.

European urology oncology·2026

Same author

Partial Nephrectomy Versus Thermal Ablation for Cystic Renal Tumors: A Registry-Based, Propensity Score Matched Analysis (UroCCR n°177).

Cardiovascular and interventional radiology·2026

Same author

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same author

ISUP 2 prostate cancer with suspicion of extraprostatic extension on MRI: Prostatectomy results and oncologic outcomes.

Urologic oncology·2026

Same author

Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

This summary is machine-generated.

Immunotherapy shows promise in prostate cancer treatment. While some agents like Sipuleucel-T are approved, others show limited success, highlighting the need for further research into effective strategies and predictive markers.

Area of Science:

Uro-oncology
Cancer immunotherapy

Background:

Immunotherapy represents a significant advancement in prostate cancer treatment.
Sipuleucel-T is the first FDA-approved autologous vaccine for prostate cancer.
Early results with agents like GVAX, tasquinimob, and anti-PD-1 have been disappointing.

Purpose of the Study:

To review the current landscape of immunotherapy in prostate cancer.
To identify challenges and future directions for immunotherapy in this disease.
To explore the potential of ipilimumab in earlier stages of prostate cancer.

Main Methods:

Review of current clinical trial data and literature on prostate cancer immunotherapy.
Analysis of efficacy and safety of various immunotherapeutic agents.
Exploration of combination strategies with other therapies.

Keywords:

Checkpoint inhibiteurs Checkpoint inhibitor Urologie Urology Vaccines Vaccins

Related Experiment Videos

Main Results:

Sipuleucel-T is an approved immunotherapy option.
Several immunotherapeutic agents have shown disappointing initial results.
Ipilimumab may be more effective in earlier stages of prostate cancer.

Conclusions:

Further research is needed to identify predictive factors and surrogate markers for immunotherapy response in prostate cancer.
Investigating the efficacy of agents alone or in combination with hormonal or bone-targeted therapies is warranted.